UCB SA

UCB SA is a multinational biopharmaceutical company headquartered in Brussels, Belgium, founded in 1928 by Emmanuel Janssen. It specializes in developing innovative medicines for severe neurological and immunological diseases, including epilepsy, Parkinson's disease, Crohn's disease, psoriasis, and autoimmune conditions, aiming to enhance patient quality of life through patient-centered research. Key products encompass neurology treatments like Keppra (levetiracetam), Briviact (brivaracetam), Vimpat (lacosamide), and Neupro (rotigotine), alongside immunology therapies such as Cimzia (certolizumab pegol) and Bimzelx (bimekizumab), plus established brands like Zyrtec and Nootropil. With over 9,000 employees across nearly 40 countries and U.S. operations centered in Atlanta, Georgia, UCB invests about a quarter of its revenue in R&D, maintaining a robust pipeline of 147 drug candidates targeting areas like nervous system, immune system, and musculoskeletal diseases. Strategic acquisitions, including Celltech in 2004, Schwarz Pharma in 2006, Ra Pharma in 2020, and Zogenix in 2022, have bolstered its focus on specialty biopharma, divesting non-core segments to prioritize high-impact innovations in biotechnology and healthcare.